Edgestream Partners L.P. Makes New $1.32 Million Investment in ACADIA Pharmaceuticals Inc. $ACAD

Edgestream Partners L.P. acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 65,328 shares of the biopharmaceutical company’s stock, valued at approximately $1,316,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of ACADIA Pharmaceuticals in the second quarter valued at $569,634,000. Palo Alto Investors LP acquired a new stake in ACADIA Pharmaceuticals during the second quarter worth approximately $72,461,629. Bank of America Corp DE purchased a new stake in shares of ACADIA Pharmaceuticals in the second quarter valued at $32,900,000. First Trust Advisors LP lifted its position in ACADIA Pharmaceuticals by 47.3% during the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after buying an additional 1,073,834 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in ACADIA Pharmaceuticals in the 2nd quarter worth about $19,244,000. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $17.11 on Friday. The company has a market cap of $2.96 billion, a PE ratio of 8.11 and a beta of 0.87. ACADIA Pharmaceuticals Inc. has a 12 month low of $15.85 and a 12 month high of $30.96. The company has a fifty day moving average price of $20.80 and a two-hundred day moving average price of $23.18.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.11. ACADIA Pharmaceuticals had a return on equity of 8.90% and a net margin of 30.13%. The company had revenue of $342.30 million during the quarter, compared to the consensus estimate of $332.58 million. During the same period in the previous year, the firm posted $0.42 earnings per share. ACADIA Pharmaceuticals’s quarterly revenue was up 22.8% compared to the same quarter last year. Equities research analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

ACAD has been the topic of a number of recent analyst reports. BMO Capital Markets cut their price target on shares of ACADIA Pharmaceuticals from $36.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, September 24th. Bank of America reissued a “buy” rating and set a $14.50 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Canaccord Genuity Group raised their target price on ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the company a “buy” rating in a report on Friday, November 6th. William Blair set a $33.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, September 28th. Finally, Wall Street Zen downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 4th. Thirteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.13.

Check Out Our Latest Stock Analysis on ACADIA Pharmaceuticals

Insider Transactions at ACADIA Pharmaceuticals

In related news, EVP Mark Schneyer sold 3,321 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $20.88, for a total value of $69,342.48. Following the sale, the executive vice president directly owned 71,322 shares in the company, valued at $1,489,203.36. This trade represents a 4.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 26.20% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Profile

(Free Report)

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.

See Also

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.